---
title: Assess arm endurance measurement reliability
nct_id: NCT06482502
status: RECRUITING
sponsor: Emre Şenocak
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06482502"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06482502"
last_fetched: "2026-05-10T14:06:13.545Z"
source: "Parkinson's Pathways (curated)"
---
# Assess arm endurance measurement reliability

**Goal (in five words):** Assess arm endurance measurement reliability

**Official Title:** Investigation of the Validity and Reliability of the 6-Minute Pegboard and Ring Test in Parkinson's Patients for Upper Extremity Endurance Assessments

**Trial ID:** [NCT06482502](https://clinicaltrials.gov/study/NCT06482502)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Emre Şenocak
- **Target Enrollment:** 34 participants
- **Start Date:** 2024-05-20
- **Completion Date:** 2024-08-31
- **Conditions:** Parkinson Disease

## Summary For Families

The goal is to see whether a simple six minute pegboard and ring test gives valid, repeatable measures of arm endurance in people with Parkinson's. Participants move rings between pegs for six minutes while researchers check how consistent and accurate the results are, this is an observational assessment rather than a treatment so it does not change or interact with medications like levodopa. They are enrolling people aged 45 to 75 with mild to moderate Parkinson's (Hoehn and Yahr stage 3 or lower), who have full shoulder motion, no recent intensive rehab, and no severe heart disease, upper limb orthopedic problems, other neurological diagnoses, uncorrected vision or significant cognitive impairment, and no recent medication changes.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Hoehn \& Yahr staging ≤3 points,
* Individuals who have not undergone a rehabilitation program of at least 20 days in the last 6 months,
* Those with full upper extremity shoulder flexion and abduction active joint range of motion.

Exclusion Criteria:

* Those with severe heart disease such as heart failure, cardiac arrhythmia, hypertension,
* People with any orthopedic problem that will affect the upper extremity,
* Having a secondary neurological disease diagnosis,
* Having vision impairment that may affect measurement methods (not corrected by glasses),
* Having a cognitive disease that may cause difficulty in following the researchers\' commands,
* Those who had changes in their medical use during the test (dose increase/decrease, drug change
```

## Locations (1)

- İstanbul Medilife Beylikdüzü Hospital, Istanbul, Turkey (Türkiye) _(41.0138, 28.9497)_
  - Call Center — (CONTACT) — +90 (212) 866 80 80 — info@medilife.com.tr
  - Adem Aktürk, PhD — (CONTACT) — +90 533 310 23 15 — aakturk@gelisim.edu.tr

## Central Contacts

- Emre Şenocak, PhD — (CONTACT) — +90 553 569 56 92 — emre.senocak@windowslive.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06482502*  
*HTML version: https://parkinsonspathways.com/trial/NCT06482502*  
*Source data: https://clinicaltrials.gov/study/NCT06482502*